Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Handle URI:
http://hdl.handle.net/10754/620939
Title:
Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
Authors:
Gadhoum, Samah; Madhoun, N. Y.; AbuElela, Ayman ( 0000-0002-4529-3156 ) ; Merzaban, Jasmeen S. ( 0000-0002-7276-2907 )
KAUST Department:
Biological and Environmental Sciences and Engineering Division
Citation:
Gadhoum SZ, Madhoun NY, Abuelela AF, Merzaban JS (2016) Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy. Leukemia. Available: http://dx.doi.org/10.1038/leu.2016.221.
Publisher:
Springer Nature
Journal:
Leukemia
Issue Date:
8-Aug-2016
DOI:
10.1038/leu.2016.221
Type:
Article
ISSN:
0887-6924; 1476-5551
Sponsors:
This work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.
Additional Links:
http://www.nature.com/leu/journal/vaop/ncurrent/full/leu2016221a.html
Appears in Collections:
Articles

Full metadata record

DC FieldValue Language
dc.contributor.authorGadhoum, Samahen
dc.contributor.authorMadhoun, N. Y.en
dc.contributor.authorAbuElela, Aymanen
dc.contributor.authorMerzaban, Jasmeen S.en
dc.date.accessioned2016-10-12T09:15:17Z-
dc.date.available2016-10-12T09:15:17Z-
dc.date.issued2016-08-08en
dc.identifier.citationGadhoum SZ, Madhoun NY, Abuelela AF, Merzaban JS (2016) Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy. Leukemia. Available: http://dx.doi.org/10.1038/leu.2016.221.en
dc.identifier.issn0887-6924en
dc.identifier.issn1476-5551en
dc.identifier.doi10.1038/leu.2016.221en
dc.identifier.urihttp://hdl.handle.net/10754/620939-
dc.description.sponsorshipThis work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.en
dc.publisherSpringer Natureen
dc.relation.urlhttp://www.nature.com/leu/journal/vaop/ncurrent/full/leu2016221a.htmlen
dc.rightsThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.en
dc.titleAnti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapyen
dc.typeArticleen
dc.contributor.departmentBiological and Environmental Sciences and Engineering Divisionen
dc.identifier.journalLeukemiaen
dc.eprint.versionPublisher's Version/PDFen
kaust.authorGadhoum, Samahen
kaust.authorMadhoun, N. Y.en
kaust.authorAbuElela, Aymanen
kaust.authorMerzaban, Jasmeen S.en
All Items in KAUST are protected by copyright, with all rights reserved, unless otherwise indicated.